Beverages Dashboard.
A reference hub on Japan's four listed beverage and alcoholic-drinks majors.
Four names inside the same TSE bucket, four orthogonal discounts, and not one consolidated multiple that survives contact with the segments underneath it. Suntory Beverage & Food is the bucket's only ex-cash return above its cost of capital — held under a 59.48% parent, priced at its decade floor. Kirin is a listed pharmaceutical franchise wearing a brewer's clothes, re-rated +38% and now slightly above its own sum of the parts. Asahi is a deleveraging roll-up whose cheapness is largely earned once the yen is normalised out. Coca-Cola Bottlers Japan is a pure converter whose business income doubled — roughly half of it on a depreciation reset — and re-rated above its decade ceiling. The shared finding is the one the cross-work landed on: every dislocation the bucket carried twelve months ago has closed or inverted.
The four names sit inside the same TSE bucket but share almost nothing else. Suntory Beverage & Food (2587.T), Coca-Cola Bottlers Japan (2579.T), Kirin Holdings (2503.T) and Asahi Group Holdings (2502.T) carry four economic archetypes — an internationalised brand owner, a pure franchise converter, a brewer wrapped around a listed pharmaceutical engine, and a leveraged M&A roll-up mid-repair. The thing the dashboard sorts is not who is cheap. It is why each is cheap, because the discount has a different cause in every case, and the cause decides whether it ever closes.
Twelve months ago the four discounts read as four dislocations to harvest. They no longer do. Two closed by re-rating — Kirin up 38% on the year as the conglomerate discount inverted into a slight premium, and Coca-Cola Bottlers up 74% as the price-to-book bid ran the multiple above its own decade ceiling. The other two closed by arithmetic rather than by price: normalise the weak yen out of Asahi's and Suntory's reported margins and most of the optical cheapness dissolves on its own. The cross-work lands on one number that frames the whole hub — zero of the four offer an actionable entry at spot, and weighted fair value sits below the price in all four.
What follows sits in three layers. The economic engine and the cross-bucket inputs describe what the four share — a consolidated line that misleads, an exposure to the yen, and a governance reform that pays the wrong thing. The archetype map and the names section sort them by the nature of the discount. The mispriced reads and the structural watchlist track what each consensus is reading wrong and what dated print would force a reframing. The single transferable discipline across the bucket: read the segments, normalise the currency, and never trust a single multiple stretched across businesses this different.
The single most decisive structural variable across the bucket is that every name is a sum of the parts pretending to be one line. Kirin reports a 47.6% consolidated gross margin that looks like a premium franchise and is in fact the weight of a patented pharmaceutical business — Kyowa Kirin, a ~74% gross margin, separately listed — pulling up a beverage gross margin of roughly 38–39% that is no better than Asahi's. Suntory's 8.7% group operating margin is the blend of a European pole earning 15.8% on 23% of revenue and a Japanese volume base earning 6.4% on 43% — a dispersion near 900 basis points that makes the consolidated multiple the wrong instrument by construction. Asahi runs a 12.9% return on assets in Japan against 3–4% offshore, the offshore drag living entirely in the goodwill rather than the operations. Coca-Cola Bottlers runs a 740-basis-point spread between OTC at ~9.2% and vending at ~1.8%, the consolidated margin set by mix shift rather than by any uniform improvement.
The return inverts the margin ranking, and that inversion is the second story. Suntory's highest-margin pole, Europe, is its least capital-efficient at a 9.0% return on capital, because the acquisition premium for Orangina and Lucozade — 47% of group non-current assets — sits immobilised in its capital base; the value is created as much in the Americas and Asia. The cleanest case in the bucket is Asahi: its reported return on capital of 4.9% sits below a 5.5% cost of capital, but strip the acquired goodwill and the same operations earn roughly 37% — a gap of about 32 points, the widest here. Any consolidated return metric that includes the goodwill measures the price of the deal, not the quality of the business under it. The diagnostic the whole bucket rests on is the split between ex-cash and ex-goodwill return, which neither reported ROIC, nor margin, nor the P/E can see.
Cash conversion completes the picture and ranks the names against their own reputations. Asahi, the name with the heaviest capital, is the best converter — free cash flow at 110% of operating profit, a 12.9% free-cash-flow yield. Suntory, framed as the bucket's quality grower, is the worst — FCF/EBIT collapsed from 98% in FY2019 to 44% in FY2025 as growth capex nearly doubled without lifting the return on capital. Kirin is erratic, mined by a peak-capex pharma leg and a cash-conversion cycle drifting to 129 days. Coca-Cola Bottlers flatters its free cash flow by running maintenance capex below depreciation, so owner earnings of about ¥40bn sit below the headline. Most of the dispersion is the capex cycle and the goodwill, not the operations.
The thread is that the consolidated line becomes an unreliable tool the moment intra-name segment dispersion clears roughly 500 basis points — and all four clear it. Suntory at ~900, Coca-Cola Bottlers at 740, Kirin spanning a 20.6% pharma margin against a low-single-digit health-supplements return, Asahi spanning a 12.9% domestic return against a goodwill-crushed 3–4% offshore. A correct read requires a sum of the parts on three of the four and a strict ex-goodwill, ex-currency lens on every one. The market has priced the easy version of each and left the segment version on the table — but, as the names section shows, the leftover is no longer a positive asymmetry.
The first cross-bucket input is the yen, and its signal here is the opposite of what it looks like. Both internationalised names have been flattered by the weak currency — Asahi with 54% of revenue offshore, Suntory with a similar share — and in both cases the reported margin overstates the structural earnings power. Suntory's Q1 FY2026 grew +11.2% reported against +6.1% currency-neutral, a ~5-point gap; Asahi's managerial Core operating profit fell −4.6% at constant currency over the first nine months of 2025 even as the reported line held. Normalising overseas earnings to the house ¥130/$ mid-cycle is not a refinement; on three of the four names it is the difference between a stock that looks cheap and one that does not. The decade of market history is unambiguous that the weak yen has never been paid through into the price — the market sees through it — so the modelling discipline is to normalise first and value second. Coca-Cola Bottlers, 100% Japan, is the lone name immune to the adjustment, which is precisely why its overvaluation owes nothing to currency.
The second input is the TSE governance reform, which has reliably paid the wrong thing. The price-to-book bid rewards a low optical book repaired by self-help, not underlying quality or clean governance. Coca-Cola Bottlers — the weakest economic model in the bucket, return on capital below its cost on both tangible and total capital — re-rated from 0.48x to 1.78x book on a buyback and a destroyed-book denominator. Suntory — the best ex-cash quality, with a listed subsidiary structure that the reform was designed to address — was ignored, its 1.0x-book floor untouched. The lesson the bucket teaches is to correlate any re-rating to the entry price-to-book and the self-help intensity, never to the return on capital. The reform does not crystallise quality discounts; it pays optical ones.
The third input runs through the structural decline of Japanese consumption and the regulated and imported costs sitting on top of it. Japanese beverage and beer volume is in secular decline of roughly −0.7% to −1% a year on demographics, held up by price across Suntory's domestic base, Asahi's beer line and Coca-Cola Bottlers' vending channel — real pricing power, but on a shrinking base. The harder, name-specific cost is administered: Kirin's patented pharmaceutical leg, the single source of genuine recurrence in the bucket, faces a −13% Japanese drug-price revision in FY2026 that accounts for four-fifths of the group's guided profit decline — the quality engine and the source of the erosion are the same leg. Two dated tailwinds sit against the drag: the 2026 unification of Japan's beer excise, which favours real-beer premium and which the market underprices at Asahi, and a lagged coffee-input softening for Coca-Cola Bottlers' Georgia line. Neither reverses a diagnostic; both are bounded. There is no aggregate tailwind to lean on — any outperformance has to come from a specific corporate act.
| Archetype | Name | Read |
|---|---|---|
|
Internationalised brand owner
Quality under a controlling parent, priced at the floor
|
Suntory Beverage & Food 2587.T | The bucket's only ex-cash return above its cost of capital, trading at its decade low on every multiple — 14.3x forward, 6.5x EV/EBITDA, 1.02x book — for reasons of control rather than fundamentals. Suntory Holdings owns 59.48% and has paid no buyback in ten years at 1.0x book. Normalise the yen out and price Europe on its 9.0% return rather than its 15.8% margin and the sum of the parts lands near ¥4,050, just under spot. The one un-priced lever is an undated governance act. Weighted fair value −6%; the floor makes the skew conditionally favourable. |
|
Brewer + listed pharma engine
SOTP crystallised — and now slightly overshot
|
Kirin Holdings 2503.T | Not a brewer but a capital allocator carrying Kyowa Kirin — a 20.6% margin, separately listed, markable to its own quotation — plus a San Miguel stake and a beer business managing volume decline by price. The +38% year already harvested the conglomerate discount the file was written to anticipate; marked part by part the sum reconstructs ~14% below the market cap. The next dated event runs the other way: a −13% pharma price revision, four-fifths of the guided profit decline. Operating engine ex-goodwill ~11%, dividend never cut. Weighted fair value −14.6%. |
|
M&A roll-up, mid-repair
Operations institutional, capital still heavy
|
Asahi Group Holdings 2502.T | Optically deep value — 0.81x book at a decade low, a 12.9% free-cash-flow yield, free cash flow at 110% of operating profit and roughly 37% on capital ex-goodwill. But reported return on capital of 4.9% sits below its cost, the gap is the price paid once at acquisition, and 54% offshore revenue flatters the margin through the weak yen. Normalised, the regional sum of the parts lands at ¥1,410, below spot. The whole case is binary and dated: the 8 July FY2025 actuals resolve the Oceania impairment test, after a −43.7% nine-month drop. Weighted fair value −10.8%. |
|
Pure franchise converter
Real recovery, half of it accounting, fully priced
|
Coca-Cola Bottlers Japan 2579.T | An industrial and logistics operator running ~90% of the Coca-Cola system's Japanese volume, buying concentrate at a price it cannot set, earning a network-execution margin — never a brand margin. Business income doubled to ¥24.5bn, but roughly 46% of the gain is a non-cash depreciation reset; the operational half is real and a record, on a franchise smaller than in 2018. The clean EV/EBITDA of 10.9x sits above the 10.3x decade ceiling. The negative read is documented but the short is inexecutable — a 4.3pp buyback, the PBR bid, +74% momentum. Weighted fair value −20.5%. |
The only name in the bucket whose return on capital clears its cost ex-cash — and the one trading at its decade low on every multiple, held under a 59.48% parent. Pull the consolidated 8.7% margin apart and the cheapness has three quieter causes than the inherited "confiscated quality" reading: a base effect that turns +7.6% headline EPS growth into ~2% real IFRS compounding, a European margin pole on a low 9.0% return, and a leak of profit to minority joint ventures. The cellular sum of the parts lands near ¥4,050 against a ¥4,358 spot — fairly valued at its floor, not a bargain.
The one un-priced lever is an undated governance act: a buyback at 1.0x book, a parent-stake reduction, a royalty cap. Ten years of market has declined to pay through the lock, and the sectoral law is that performance alone will not re-rate the name — only a corporate event does. The floor at ~¥3,800 / 0.9x book bounds the realistic downside to ~−13% against a catalyst-driven +22%, which is the bucket's only favourable skew. Sizing nil until one materialises.
Pull the consolidated multiple apart and Kirin is a capital allocator carrying a listed pharmaceutical franchise — Kyowa Kirin at a 20.6% margin, markable to its own quotation — a San Miguel stake, and a beverage business managing decline by price. The inherited reading was a conglomerate discount waiting to crystallise. After a +38% year it has not just closed but inverted: marked part by part, the sum reconstructs ~14% below the market cap. The February 2026 capital pivot — Four Roses sold, an ¥80bn buyback, 10.7% of capital retired, a 5% dividend-on-equity floor — is the catalyst the file was written to anticipate, already executed and paid.
The operating engine ex-goodwill and ex-equity-method earns ~11%, five points over its cost, and the dividend has never been cut. But the next dated event runs against the re-rating: Kyowa Kirin is guided −13% in FY2026 on the administered drug-price revision, four-fifths of the group's guided profit decline — the leg that justifies the mix re-rating is the leg being cut. The weighted asymmetry is negative and skewed, +11% against −34%. The level that re-arms a long is a pullback toward ¥2,400.
The optical case reads as deep value: 0.81x book at a decade low, a 12.9% free-cash-flow yield, an operating engine that converts at 110% and earns roughly 37% on capital once the acquired goodwill is stripped out. The reported 4.9% return below a 5.5% cost of capital, and the ¥3.35tn of goodwill, are the price paid once at acquisition — not a failure of the operations underneath. Normalise the weak yen out of a margin where 54% of revenue is offshore, and price the impairment risk the −43.7% nine-month Oceania drop has opened, and the regional sum of the parts lands at ¥1,410, below the ¥1,510 spot. The discount is largely earned.
What is left is narrow, binary and dated. The cardinal variable — whether the Oceania unit is impaired — is unobservable until the 8 July FY2025 actuals, which resolve the impairment test and the cyber normalisation together. A material impairment resets the book downward, lifts price-to-book toward 1.0x with no gain to the holder, and confirms the value-trap signature. No impairment plus a Core operating profit at or above guidance, with a pullback below ~¥1,200, would open a favourable asymmetry. The bucket's nearest and sharpest catalyst.
The one pure converter in the bucket: no brand, no concentrate it can price, no business outside Japan. Business income doubled from ¥12.0bn to ¥24.5bn and the share is up 74%, but a proxy decomposition puts roughly 46% of the gain in the depreciation line — a non-cash tailwind that flatters the margin without improving the cash. The operational 54% is genuine, and FY2025 is the highest the certified series has ever printed, but it sits on a franchise smaller than it was in 2018, earning a tangible return below its cost of capital. The clean EV/EBITDA of 10.9x sits above a 10.3x decade ceiling; owner earnings of ~¥40bn fall short of the 5% margin the multiple assumes.
The negative read does not translate into a position. Weighted fair value is ¥3,424, some 20.5% below spot, but a 4.3pp buyback yield, an active PBR bid and +74% momentum make shorting a self-help name a squeeze trap. The bias is short; the trade is not. There is no actionable entry: too negative to be long, too firm to be short. A reflux below ~¥3,600 would be the cleaner route to a long entry.
| Metric | Who it tests | What would change the read |
|---|---|---|
| Currency-neutral operating profit | Suntory B&F · 2587.T | Negative ex-FX through FY2026 with an ex-FX margin below 9% falsifies the structural-margin reading and pulls fair value toward the bear. A return to currency-neutral growth above a 9% margin confirms the quality leg. |
| Governance act | Suntory B&F · 2587.T | A buyback above 3% of capital, a parent-stake reduction, or a royalty cap under the incoming CEO or new mid-term plan moves the dossier from watchlist to long. The only re-rating lever; not signalled today. |
| Kyowa Kirin pharma operating profit | Kirin · 2503.T | A margin holding above 17% in FY2026 with FY2027 guidance returning to growth confirms durability. A revision beyond −5% past the guided −13% confirms erosion and pulls fair value toward ¥1,864. |
| Oceania segment profit and impairment test | Asahi · 2502.T | The 8 July FY2025 actuals decide. A material impairment resets the book, lifts price-to-book toward 1.0x with no holder gain, and confirms the trap toward ≤¥1,000. A return toward the ~¥43bn run-rate confirms the unit creates value. |
| Net Debt/EBITDA on the agency convention | Asahi · 2502.T | Clearing 2.0x without an impairment is the only hard trigger for a price-to-book re-rating; until then the discount is earned. The gross convention reads ~3.06x. |
| Business-income margin once the D&A tailwind exhausts | Coca-Cola Bottlers · 2579.T | A margin held ≥5% across FY2026–27 with stable maintenance capex confirms a structural recovery. Capping below 4%, with vending revenue falling more than −3% over two consecutive quarters, confirms the value trap toward ¥2,574. |
| USD/EUR/AUD-JPY normalised assumption | Cross-bucket | A sustained move toward the house ¥130/$ mid-cycle compresses the FX-flattered margin at Suntory and Asahi — taking a ~5 to 9% haircut out of overseas earnings, unevenly distributed. Coca-Cola Bottlers, 100% Japan, is immune. |
The framework rests on the assumption that the bucket's four discounts are now correctly priced or earned — that the re-ratings at Kirin and Coca-Cola Bottlers have closed real dislocations and the FX normalisation at Suntory and Asahi has dissolved optical ones. The cleanest single invalidation is a governance act at Suntory: a material buyback at 1.0x book, a reduction in the 59.48% parent stake, or a cap on the intra-group royalty would reframe a fairly-valued floor as a resorbable discount and open the bull path toward ~¥5,340. The lever is observable on the published calendar and is the one path in the bucket that pays without a fundamental relay. It is not signalled today.
The second invalidation is dated and imminent. Asahi's 8 July FY2025 actuals resolve the Oceania impairment test and the cyber normalisation together: no material impairment with a Core operating profit at or above guidance, against a pullback below ~¥1,200, would move the dossier from watchlist to long — the bucket's nearest favourable asymmetry. The symmetrical risk runs the other way across the bucket, and it is allocation, not operations: a fresh debt-financed acquisition at Asahi or Kirin deploying the balance sheet below the cost of capital, a European goodwill impairment at Suntory, or growth capex reinvested into the declining vending channel at Coca-Cola Bottlers would each convert a reversible timing question into a permanent impairment and force a complete re-underwriting. None is signalled now; each sits inside a balance sheet that currently funds discipline.
This dashboard is the reference document for sub-industry 02c. Single-name memos, recent Newsflow Monitor issues, and Consumer Pulse mentions touching this universe are listed below.
- 2587.T Suntory Beverage & Food Published
- 2503.T Kirin Holdings Published
- 2502.T Asahi Group Holdings Published
- 2579.T Coca-Cola Bottlers Japan Published
- — Beverages Newsflow · Issue 01
- — Consumer Pulse · Beverages
The information provided on this website is for informational and educational purposes only and should not be construed as financial, investment, legal, or tax advice. All content reflects the personal opinions, interpretations, and analyses of the author at the time of writing and is subject to change without notice. Nothing contained herein constitutes, or should be interpreted as, a recommendation, solicitation, or offer to buy or sell any securities, financial instruments, or other investment products. The author is not a licensed financial advisor, broker, or investment professional. Any references to specific assets, markets, or strategies are illustrative in nature and do not constitute personalized investment advice. Investing in financial markets involves risk, including the potential loss of capital. Past performance is not indicative of future results. Readers are solely responsible for their own investment decisions and should conduct their own independent research and due diligence before making any financial commitments. You are strongly encouraged to consult with a qualified financial advisor, legal professional, or other relevant specialist before making any investment or financial decisions. By accessing and using this blog, you agree that the author shall not be held liable for any direct or indirect losses, damages, or consequences arising from the use of, or reliance on, the information presented herein. All content is provided "as is" without any warranties of completeness, accuracy, or reliability.